FDA calls for healthcare worker feedback to enhance monitoring of AI-enabled medical devices in real-world settings.
Key Details
- 1FDA opens comment window (Sept 30–Dec 1) for real-world monitoring of AI-equipped devices.
- 2Agency seeks input on detection and mitigation of data/model drift and performance changes.
- 3Most current evaluations rely on static retrospective testing, which FDA says is insufficient.
- 4End-users with experience of deployed AI tools are specifically invited to contribute insights.
- 5Recent breakthroughs: FDA Breakthrough Device status for Aidoc's AI triage solution; new AI approaches to body composition assessment (Mass General Brigham), and mammogram-based CVD risk prediction.
Why It Matters
Robust post-market monitoring and ongoing user feedback are vital as more AI tools are deployed in radiology and medical imaging. These regulatory efforts shape safe, effective, and continually improving AI integration in clinical practice.
Source
AI in Healthcare
Related News
•Cardiovascular Business
AI Uses Mammograms to Predict Women’s Cardiovascular Disease Risk
AI algorithms can analyze mammograms to predict cardiovascular disease risk, expanding the utility of breast imaging.
•Health Imaging
Most FDA-Cleared AI Devices Lack Pre-Approval Safety Data, Study Finds
A new study finds fewer than 30% of FDA-cleared AI medical devices reported key safety or adverse event data before approval.
•Radiology Business
Analysis Finds Lax Reporting on Key Safety Data in FDA-Cleared AI Devices
Less than 30% of FDA-cleared AI devices shared key safety and adverse event data before approval, raising regulatory concerns.